Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gr Biosystems Inc. operates in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This prosecution is being managed by 1 distinct examiner in 1 distinct art unit, reflecting a very narrow focus for the company's current biotechnology filings.
KASSA, TIGABU is the busiest examiner for the portfolio, with 1 busiest examiner pending action. This single action represents the entire active workload for the company. Prosecution strategy is therefore focused on the specific requirements of this one examiner and the standards of the single art unit involved in the biotechnology sector. Success for the company's current intellectual property depends on navigating the review process of this one individual, making examiner-specific research a critical component of the prosecution plan.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18912302 | COMPOSITIONS FOR TREATING PERIODONTAL DISEASES | KASSA, TIGABU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18912302 | COMPOSITIONS FOR TREATING PERIODONTAL DISEASES | KASSA, TIGABU | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18912302 | COMPOSITIONS FOR TREATING PERIODONTAL DISEASES | KASSA, TIGABU | 1619 | §102§103 | Non-Final OA | — | Pending | Oct 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGr Biosystems Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tigabu Kassa has the most, with 1 of Gr Biosystems Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
